Background: Historically, diagnosis of epidermolysis bullosa has required skin biop-
| INTRODUCTION
Epidermolysis bullosa (EB) is a group of rare genetic disorders all associated with extreme skin fragility. 1 It is caused by mutations in genes that encode proteins located in the epidermis, basement membrane zone, and dermis and has an estimated incidence of 20 per million in the United States and 3.8 to 20.1 per million worldwide. [2] [3] [4] A variety of mutations in 19 genes have been identified. 1 This article details the high-throughput next-generation sequencing method used and provides the results on the first 43 patients tested. This method has been used to sequence the EB genes in the EB SEQ assay. Clinically, there are four main types of EB 5 : EB simplex (EBS), caused by mutations in 14 different genes; 1, 6 junctional EB (JEB), now known to be caused by mutations in eight different genes; 1, 7 dystrophic EB (DEB), 8 caused by mutations in collagen 7A1 (COL7A1); and Kindler syndrome, 9 caused by mutations in FERMT1 (Table 1) . We included two genes listed for convenience under the EBS subtype, carbohydrate sulfotransferase 8 (CHST8) 6 and corneodesmosin (CDSN), 10 because they have been reported in fragile skin syndromes. The 2014 EB classification lists only 11 genes for EBS. 1 There are many DOI: 10.1111/pde.13392 subtypes within the four main types of EB, distinguished according to mode of inheritance, type of mutation(s), and clinical characteristics.
The Cincinnati Children's EB Center provides interdisciplinary, specialized expertise to more than 300 patients. Knowing specific genetic mutations will enable better correlation with the expressed phenotypic characteristics. 11, 12 In 2015, Tenedini and colleagues reported the use of ampliconbased next-generation sequencing (NGS) to successfully screen for all types of EB in one sample. 13 The Division of Human Genetics at 
| MATERIALS AND METHODS
Two hundred nanograms of DNA were isolated from blood and saliva (PureGene DNA Kit, Qiagen, Hilden, Germany instrument were subjected to adapter trimming, followed by generation of FASTQ files. 14 The FASTQ files were then processed through NGS data analysis pipeline. The high-quality sequence reads were filtered and mapped to a target-specific reference file (GB file) for target-specific alignment and to human genome build 19 (hg19)
GRCh37 for whole-genome alignment using NextGENe software 
| RESULTS
The EBSEQ assay's clinical is 75% to 98%, and analytical sensitivity is 99%, based on literature review of published information for base substitutions and small deletions and duplication. We have tested samples from 43 patients using EBSEQ. Significant mutations were identified in 42 of the 43 probands (Table 2) . We have also confirmed mutations in 11 family members using targeted Sanger sequencing. Samples from five subjects with known mutations detected in other diagnostic laboratories were used to validate the assay. Fifty-five different clinically significant mutations have subsequently been identified in the 42 probands from 41
families. Of the 55 significant mutations found, 15 appear not to have been previously reported. We identified 11 cases of EBS (Table 3) , five cases of JEB (Table 4) , 11 cases of dominant dystrophic EB (Table 5) , and 15 cases of recessive dystrophic EB (Table 5 ). In total, we identified significant mutations in five of the 21 genes tested (KRT5, KRT14, LAMB3, COL17A1, COL7A1). We also found 52 variants of uncertain clinical significance (VUCS) that did not appear to provide primary diagnoses in 17 additional EB genes (PLEC, ITGA3, ITGB4, ITGA6, DST, FERMT1, EXPH5, PKP1, CDSN, DSP, LAMB3, COL7A1, COL17A1, KRT14, PKP1, JUP) (Table S1) .
We found that, in two patients (1 and 10), we were able to detect significant mutations in KRT14 and KRT5 that had not been previously found in another commercial assay in these individuals.
We detected likely pathogenic mutations in all but 1 of the 43 probands we tested. In addition, this technology was able to detect a small 52-base pair deletion in COL7A1 gene. Diagnosis in some patients was not straightforward, and skin biopsies for direct immunofluorescence mapping and transmission electron microscopy, as well as parental genetic analysis, were used to confirm some diagnoses. The turnaround time from receipt of samples in the laboratory to generation of the completed report ranged from 3 to 6 weeks (average 4 weeks).
| DISCUSSION
The EBSEQ assay is a comprehensive NGS test to diagnose EB. It specifically analyzes 21 fragile skin (EB)-related genes. This report details the results from the first 43 subjects we tested after favorably comparing our assay with five previously diagnosed cases of EB. EBSEQ uses a specific library of 21 genes known to be involved in fragile skin diseases, allowing single samples to be run at any time and thus shortening the time to diagnosis. We also found EBSEQ to have high analytical reliability of 99% for base substitutions and small deletions and duplication and clinical sensitivity of 75% to 98%. EBSEQ was used in this study primarily to identify mutations in undiagnosed patients, although even when the clinical phenotype is typical of a specific diagnosis, we are studying the type and location and ultimately the consequences of these mutations to increase understanding and predict clinical severity and prognosis. 15 Tenedini and colleagues 13 recently published a similar NGS assay on 10 patients, and there is a report of a commercial laboratory (GeneDx, Gaithersburg, MD, USA) using whole-exome sequencing to screen for EB. 17 Whether a specific assay designed for EB has advantages over whole-exome sequencing screening remains to be seen as more laboratories begin to offer this test. 
